No Universal 'Best' in Robotic Surgery
If you’re shopping for a robotic surgical system in 2025, you’ve probably read all the brochures. They all promise better outcomes, faster recovery, and a lower total cost of ownership. Here’s the thing: there’s no single 'best' system. There’s only the best system for your specific surgical volume, case mix, and budget.
I’ve been handling capital equipment procurement for a mid-sized hospital network for about six years now. In my first year (2019), I made the classic mistake of pushing for a system based purely on its technical specs. I won’t bore you with the details, but let’s just say the numbers didn’t add up. My boss still brings up the 'ROI disaster of 2020' every so often.
So, if you’re looking for a sales pitch, this isn’t it. I’m writing this to help you avoid my mistakes. Based on my experience (and the hard lessons I’ve documented), here’s how to think about this decision.
The key is to understand which of these three scenarios you fall into:
- Scenario A: High-volume general surgery (500+ robotic procedures per year)
- Scenario B: Lower-volume, specialized surgery (e.g., thoracic, urology)
- Scenario C: First-time buyer, uncertain growth trajectory
Your answer will dictate whether Intuitive Surgical is a good fit, or if you should consider an alternative.
Scenario A: The High-Volume Powerhouse
This is where Intuitive Surgical’s da Vinci system (specifically the new da Vinci 5) shines. If your surgeons are doing 500+ procedures a year—think cholecystectomies, colectomies, and hernias—the math starts to work.
Here’s what I learned the hard way: the per-case instrument costs for the da Vinci are higher than most competitors. But the total cost of ownership (including service contracts and capital depreciation) can be lower if you can spread those costs over a huge volume.
My recommendation: For high-volume centers, the da Vinci is probably your best bet. The platform is mature, the surgeon training infrastructure is unparalleled, and the clinical evidence base is massive. You can quote it with confidence.
“In September 2022, I almost pushed a contract for a competitor’s system because the per-instrument cost was 20% lower. My colleague stopped me. She showed me that our 600+ procedure volume would mean 15% less uptime due to the competitor’s service model. The da Vinci was cheaper over a 5-year horizon. That was a lesson in total cost vs. unit cost.”
When the Da Vinci Isn't the Right Fit (Even for High Volume)
Look, I’m not saying it’s perfect. If your case mix is heavily weighted towards bariatrics (where you need a lot of stapling), instruments alone can eat your budget. In that case, you might want to look at a system with a more aggressive stapling partnership (like Medtronic’s, for example—though I won’t name names in this article).
The way I see it, the bigger risk is under-utilization. A system doing 300 procedures a year won’t pay back. Stick with 500+ cases/year as your benchmark.
Scenario B: The Specialized Center
This is where conventional wisdom can mislead you. Everyone assumes Intuitive’s da Vinci is the platform for specialties like urology (prostatectomies) or thoracic (lung resections). And yes, it’s excellent for those. But here’s the twist I discovered: the Ion platform might actually be a better investment for you.
Head-scratcher, right? Most buyers focus on the da Vinci because it’s the flagship. The question everyone asks is, 'Which da Vinci model should we get?' The question they should ask is, 'Do we need a multi-quadrant surgical robot, or a robotic bronchoscopy platform?' If you’re a center of excellence for lung cancer, Ion (Intuitive’s robotic-assisted bronchoscopy system) could be the smarter initial investment. It’s not a 'lesser' alternative—it’s a different tool for a different job.
Here’s a real example: A hospital I consulted for in 2023 was about to buy a second da Vinci for thoracic surgery at a cost of $2.5M. I showed them the numbers for the Ion instead. The capital cost was lower, and the procedure volume for lung biopsies was growing at 30% year-over-year. They went with the Ion. They’ve been happy ever since.
So, for specialized centers, my advice is to look beyond the da Vinci brand. Intuitive is more than just one robot.
Scenario C: The First-Time Buyer
If you’re a smaller hospital or a surgical center that’s never had a robot, the temptation is to go with the market leader. That’s the safe choice, right? Not always.
Here’s my honest opinion: for a first-time buyer, I’d actually steer you toward a used da Vinci Xi or a refurbished system. The da Vinci 5 is an incredible machine, but the capital cost is eye-watering (north of $2.5M, depending on configuration). A used Xi, on the other hand, can be acquired for $800k-$1.2M, and the instrument costs are lower than for the newer model.
I once pushed a first-time buyer into a brand-new system. The board approved it, but the financial pressure forced them to run 50% more cases than initially planned just to break even. That pressure led to rushed cases and surgeon burnout. The board wasn’t happy. My credibility took a hit.
If I could go back, I’d say: 'Start with a used system. Prove the program. Build the volume. Then upgrade.'
One more thing: Don’t overlook the training costs. Intuitive’s training is excellent, but it’s not cheap. Factor that into your first-year budget.
How to Choose Your Path
So, which scenario fits you?
- Are you a high-volume center (500+ cases/year) for general surgery? Go with the da Vinci 5. It’s the best-in-class workhorse.
- Are you a specialized center (e.g., thoracic, urology)? Look at the Ion platform or a dedicated solution. Don’t automatically default to the da Vinci.
- Are you a new program or lower-volume center? Seriously consider a refurbished da Vinci Xi to keep your financial risk low and your program stable.
I’ve been doing this long enough to know that the 'right' answer depends on your situation. What I can tell you is this: don’t let the hype of a new model or the fear of a 'non-leader' system cloud your judgment. Do the math for your case volume and case mix. That’s how you avoid the mistakes I made.
If you’re still unsure, start with a pro forma analysis. Project your procedure volume for three years. Then run the numbers for a da Vinci vs. a used system vs. an alternative platform. The answer is almost always in the data.